Extended Follow up of Patients Treated with Bendamustine for Lymphoid Malignancies
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Teaser Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
More News: Acute Leukemia | Acute Myeloid Leukemia | Bladder Cancer | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Kidney Cancer | Leukemia | Lung Cancer | Lymphoma | Melanoma | Myelodysplastic Syndrome | Myeloma | Non-Hodgkin's Lymphoma | Prostate Cancer | Rituxan | Sarcomas | Skin | Skin Cancer | Study | Toxicology | Treanda